Hikal Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹434 Cr +36.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
H

Hikal Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Hikal Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹552Cr
+7.4% YoY
+23.4% QoQ
Net profit
₹50Cr
+48.1% YoY
+191.9% QoQ
Margin
22.34%
+4 pp YoY
+6.2 pp QoQ
Price₹216
Market cap₹2.7K Cr
P/E63.4

The short version

Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects. Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12).

From Hikal Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects.
  • Crop Protection business anticipated to remain flattish in FY '26 with growth resuming from FY '27 onwards as market stabilizes and new product launches ramp up.
  • Animal Health segment showing strong momentum with a healthy pipeline and increasing regulatory oversight, signaling future growth potential.
  • New high-potency chemistry laboratory coming online by Q3 FY '26, expected to increase participation in high-value RFQs and add to growth.
  • CDMO segment managing a robust pipeline of 12 to 15 new opportunities, supporting long-term growth and diversification.

2 more points from Hikal Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Hikal Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27.
  • Investment is focused on capacity, talent, and technology to support scale readiness and enhance competitive edge.
  • A new high-potency chemistry laboratory (mini pilot plant) is being commissioned by Q3 FY '26 to enable participation in high-potency anticancer drug projects and early clinical trial material production.
  • Continued investments are being made in R&D, allocating 4-5% of revenue toward innovation.

2 more points from Hikal Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The Crop Protection CDMO division is managing a robust pipeline of 8 active projects with existing and new strategic customers.
  • The Animal Health segment has received validation for 8 products and is working with multiple innovators.
  • The Pharma business has around 12 to 15 products in advanced stages of development and commercialization, up from 6 to 9 the previous year (more than 50% increase).
  • The new high-potent chemistry lab expected to be operational by Q3 FY '26 will increase participation in RFQs, potentially boosting project inflow by 30-40% or more.

2 more points from Hikal Ltd's call on order book

Create a free account to keep reading this call

Hikal Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Hikal Ltd Q4 FY25 results — key figures

Hikal Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue552514+7.4%448+23.4%
Operating profit (EBITDA)12394+30.7%72+71.2%
Operating margin22.34%18.36%+4 pp16.1%+6.2 pp
Profit before tax6847+44.4%24+187%
Net profit (PAT)5034+48.1%17+191.9%
EPS (₹)4.072.75+48%1.39+192.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹434 Cr, net loss ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hikal Ltd Q4 FY25 results?

Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects. Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12).

What is Hikal Ltd share price analysis?

Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hikal Ltd planning capital expenditure?

Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27.

Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.